PMID- 30067409
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20230928
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Print)
IS  - 1520-9156 (Linking)
VI  - 20
IP  - 8
DP  - 2018 Aug
TI  - Prediction Quality of Glucose Trend Indicators in Two Continuous Tissue Glucose 
      Monitoring Systems.
PG  - 550-556
LID - 10.1089/dia.2018.0112 [doi]
AB  - BACKGROUND: Continuous interstitial glucose monitoring (CGM) systems often 
      provide glucose trend indicators (e.g., arrows) in addition to current glucose 
      values. These indicators are recommended to be used in therapeutic decisions, 
      because they are ascribed predictive qualities by CGM system manufacturers and 
      expert committees. This study assessed how reliably trend indicators match future 
      glucose change, because such information is missing. METHODS: In a clinical 
      trial, two different CGM systems were used by 20 participants, with two sensors 
      of each system per patient. Participants used the systems for 14 days with three 
      study site visits (48 h each). During study site visits, glucose trend 
      indicators, as displayed by the CGM systems, were recorded at least once per hour 
      during daytime and once at night in a diary. In addition, CGM data were 
      downloaded from the devices. Trend indicators were compared with glucose change 
      calculated from CGM data >30 min after recording the trend indicator. RESULTS: 
      Approximately 60% of trend indicators matched the glucose change calculated from 
      CGM data. More than 10% of trend indicators differed by at least two trend 
      indicator categories. Focusing on trend indicators recorded around carbohydrate 
      (CHO) intake and insulin deliveries resulted in approximately half of trend 
      indicators matching the calculated glucose change. CONCLUSIONS: Trend indicators 
      do not always match future glucose change, especially within the first few hours 
      after CHO intake and insulin deliveries. Manufacturers' labeling and 
      recommendations should reflect this, so that CGM users can make informed 
      decisions.
FAU - Freckmann, Guido
AU  - Freckmann G
AD  - Institut fur Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH 
      an der Universitat Ulm , Ulm, Germany .
FAU - Link, Manuela
AU  - Link M
AD  - Institut fur Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH 
      an der Universitat Ulm , Ulm, Germany .
FAU - Westhoff, Antje
AU  - Westhoff A
AD  - Institut fur Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH 
      an der Universitat Ulm , Ulm, Germany .
FAU - Kamecke, Ulrike
AU  - Kamecke U
AD  - Institut fur Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH 
      an der Universitat Ulm , Ulm, Germany .
FAU - Pleus, Stefan
AU  - Pleus S
AD  - Institut fur Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH 
      an der Universitat Ulm , Ulm, Germany .
FAU - Haug, Cornelia
AU  - Haug C
AD  - Institut fur Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH 
      an der Universitat Ulm , Ulm, Germany .
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adult
MH  - Blood Glucose/analysis
MH  - Blood Glucose Self-Monitoring/*methods
MH  - Diabetes Mellitus, Type 1/*blood/drug therapy
MH  - Female
MH  - Glucose/*analysis
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Insulin Infusion Systems
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Physiologic/*methods
MH  - Young Adult
PMC - PMC6080115
OTO - NOTNLM
OT  - Blood glucose monitoring replacement
OT  - Continuous glucose monitoring
OT  - Nonadjunctive use
OT  - Trend arrow
OT  - Trend indicator.
COIS- G.F. is General Manager of the IDT (Institut fur Diabetes-Technologie, 
      Forschungs- und Entwicklungsgesellschaft mbH an der Universitat Ulm, Ulm, 
      Germany), which carries out clinical studies on the evaluation of BG meters and 
      medical devices for diabetes therapy on its own initiative and on behalf of 
      various companies. G.F./IDT have received speakers' honoraria or consulting fees 
      from Abbott, Ascensia, Bayer, Berlin-Chemie, Becton-Dickinson, Dexcom, LifeScan, 
      Menarini Diagnostics, Novo Nordisk, Roche, Sanofi, Sensile, and Ypsomed. M.L., 
      A.W., U.K., S.P., and C.H. are employees of IDT.
EDAT- 2018/08/02 06:00
MHDA- 2018/12/12 06:00
PMCR- 2018/08/01
CRDT- 2018/08/02 06:00
PHST- 2018/08/02 06:00 [entrez]
PHST- 2018/08/02 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/08/01 00:00 [pmc-release]
AID - 10.1089/dia.2018.0112 [pii]
AID - 10.1089/dia.2018.0112 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2018 Aug;20(8):550-556. doi: 10.1089/dia.2018.0112.